KR20150108946A - 암을 치료하기 위한 방법 및 조성물 - Google Patents

암을 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20150108946A
KR20150108946A KR1020157025243A KR20157025243A KR20150108946A KR 20150108946 A KR20150108946 A KR 20150108946A KR 1020157025243 A KR1020157025243 A KR 1020157025243A KR 20157025243 A KR20157025243 A KR 20157025243A KR 20150108946 A KR20150108946 A KR 20150108946A
Authority
KR
South Korea
Prior art keywords
day
effective amount
therapeutically effective
lyase inhibitor
hydroxylase
Prior art date
Application number
KR1020157025243A
Other languages
English (en)
Korean (ko)
Inventor
알란 에이치. 아우어바크
아리 에스. 벨데그룬
Original Assignee
코우가 바이오테크놀로지, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150108946(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 코우가 바이오테크놀로지, 인크. filed Critical 코우가 바이오테크놀로지, 인크.
Publication of KR20150108946A publication Critical patent/KR20150108946A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
KR1020157025243A 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물 KR20150108946A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
US60/921,506 2006-08-25
PCT/US2007/018769 WO2008024484A1 (en) 2006-08-25 2007-08-23 Methods and compositions for treating cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097005974A Division KR20090059126A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177037293A Division KR20180003636A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20150108946A true KR20150108946A (ko) 2015-09-30

Family

ID=38916904

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020177037293A KR20180003636A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020207031218A KR20200125776A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020097005974A KR20090059126A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020157025243A KR20150108946A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020177037293A KR20180003636A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020207031218A KR20200125776A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020097005974A KR20090059126A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물

Country Status (21)

Country Link
EP (3) EP2478907B1 (ru)
JP (9) JP2010501575A (ru)
KR (4) KR20180003636A (ru)
CN (2) CN101528308A (ru)
AU (6) AU2007287098C1 (ru)
CA (1) CA2661422C (ru)
CY (2) CY1115477T1 (ru)
DK (2) DK2478907T3 (ru)
ES (2) ES2869343T3 (ru)
HK (1) HK1131577A1 (ru)
HR (2) HRP20130961T1 (ru)
HU (1) HUE054495T2 (ru)
IL (3) IL197211A0 (ru)
LT (1) LT2478907T (ru)
NO (2) NO20091190L (ru)
NZ (1) NZ597830A (ru)
PL (2) PL2061561T3 (ru)
PT (2) PT2478907T (ru)
RS (2) RS62034B1 (ru)
SI (2) SI2061561T1 (ru)
WO (1) WO2008024484A1 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478907B1 (en) 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
RU2481107C2 (ru) * 2007-10-29 2013-05-10 Такеда Фармасьютикал Компани Лимитед Средство для профилактики или лечения рака
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
KR20140053836A (ko) 2011-01-11 2014-05-08 글락소스미스클라인 엘엘씨 조합물
EP2694072B1 (en) 2011-04-01 2017-11-29 Genentech, Inc. Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
RU2014154009A (ru) * 2012-06-06 2016-08-10 Новартис Аг Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
KR102121404B1 (ko) * 2013-03-15 2020-06-11 썬 파마 글로벌 에프제트이 아비라테론 아세테이트 제제
JP2016515628A (ja) * 2013-04-04 2016-05-30 エグゼリクシス， インコーポレイテッド 癌を治療するための複合薬
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
AU2014330779A1 (en) * 2013-10-01 2016-04-07 Novartis Ag Combination
MX2016004265A (es) * 2013-10-01 2016-07-08 Novartis Ag Combinacion.
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
WO2016162229A1 (en) * 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
US20180028521A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of Treating Prostate Cancer
JOP20190244A1 (ar) * 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ249911A (en) 1992-03-31 1996-06-25 British Tech Group 17-(3-pyridyl) substituted steroids and use in pharmaceutical compositions
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
JP2003525254A (ja) * 2000-03-02 2003-08-26 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 併用化学療法
US20040092583A1 (en) * 2001-01-02 2004-05-13 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions
CA2503549C (en) 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
EP1583539A2 (en) * 2003-01-13 2005-10-12 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
EP2478907B1 (en) 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer

Also Published As

Publication number Publication date
WO2008024484A1 (en) 2008-02-28
HUE054495T2 (hu) 2021-09-28
AU2017201764A1 (en) 2017-04-06
EP2478907A2 (en) 2012-07-25
NO20200775A1 (no) 2009-03-20
CA2661422C (en) 2017-06-27
IL227746A0 (en) 2013-09-30
JP2015110577A (ja) 2015-06-18
AU2007287098C1 (en) 2018-03-15
DK2061561T3 (da) 2013-10-07
NZ597830A (en) 2013-02-22
HK1131577A1 (en) 2010-01-29
EP2478907A3 (en) 2012-08-01
AU2015221447A1 (en) 2015-09-17
PL2061561T3 (pl) 2013-12-31
AU2018271331A1 (en) 2018-12-20
EP2478907B1 (en) 2021-04-14
JP2010501575A (ja) 2010-01-21
RS52956B (en) 2014-02-28
JP6445123B2 (ja) 2018-12-26
AU2015221447B9 (en) 2017-07-20
HRP20210670T1 (hr) 2021-06-11
AU2015221447B2 (en) 2016-12-15
AU2007287098B2 (en) 2013-08-15
CA2661422A1 (en) 2008-02-28
PT2061561E (pt) 2013-10-09
DK2478907T3 (da) 2021-05-25
CN104306977A (zh) 2015-01-28
HRP20130961T1 (hr) 2013-11-22
PT2478907T (pt) 2021-05-26
AU2007287098A1 (en) 2008-02-28
KR20180003636A (ko) 2018-01-09
EP3804730A1 (en) 2021-04-14
JP2017052791A (ja) 2017-03-16
JP2022185091A (ja) 2022-12-13
LT2478907T (lt) 2021-06-25
SI2478907T1 (sl) 2021-08-31
AU2021201649A1 (en) 2021-04-08
EP2061561B1 (en) 2013-07-10
SI2061561T1 (sl) 2013-11-29
RS62034B1 (sr) 2021-07-30
JP6053279B2 (ja) 2016-12-27
NO20091190L (no) 2009-03-20
KR20200125776A (ko) 2020-11-04
CY1115477T1 (el) 2017-01-04
JP2012082215A (ja) 2012-04-26
IL257681A (en) 2018-04-30
ES2869343T3 (es) 2021-10-25
JP2018065859A (ja) 2018-04-26
AU2022206696A1 (en) 2022-08-11
JP2019059750A (ja) 2019-04-18
PL2478907T3 (pl) 2021-10-25
CY1124221T1 (el) 2022-05-27
JP2021038252A (ja) 2021-03-11
ES2428634T3 (es) 2013-11-08
CN101528308A (zh) 2009-09-09
IL197211A0 (en) 2009-12-24
JP2020114851A (ja) 2020-07-30
KR20090059126A (ko) 2009-06-10
JP6740497B2 (ja) 2020-08-12
EP2061561A1 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
JP6740497B2 (ja) 癌を治療するための方法及び組成物
US10702540B2 (en) Methods and compositions for treating cancer
US20110319369A1 (en) Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
IL94991A (en) Steroid enzyme inhibitors and / or androgen receptor antagonist, their preparation and pharmaceutical components for the treatment of androgenic diseases
KR20090060306A (ko) 비타민 ｄ 화합물 및 추가 치료제, 및 그를 함유하는 조성물을 투여하는 것을 포함하는, 암을 치료하는 방법
Kim et al. Hormonal Anticancer Drugs
Aggarwal et al. Development of abiraterone acetate, a 17-alpha hydroxylase C17, 20-lyase inhibitor as a secondary hormonal therapy in prostate cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2017101005655; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20171123

Effective date: 20190628